Trials / Completed
CompletedNCT01307267
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
A PHASE 1 STUDY OF PF-05082566 AS A SINGLE AGENT IN PATIENTS WITH ADVANCED CANCER, AND IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA (NHL)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 190 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb), in patients with solid tumors or b-cell lymphomas, and in combination with rituximab in patients with CD20 positive Non-Hodgkin's Lymphoma (NHL).
Conditions
- Lymphoma, Non-Hodgkin
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell of Head and Neck
- Malignant Melanoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-05082566 | Intravenous, Dose escalation, once per month |
| DRUG | rituximab | Intravenous, 375 mg/m2, once per week for 4 weeks |
| DRUG | PF-05082566 | IV, Dose escalation, once per month |
Timeline
- Start date
- 2011-06-21
- Primary completion
- 2019-02-20
- Completion
- 2019-02-20
- First posted
- 2011-03-02
- Last updated
- 2020-03-17
- Results posted
- 2020-03-17
Locations
42 sites across 5 countries: United States, Australia, France, Italy, Japan
Source: ClinicalTrials.gov record NCT01307267. Inclusion in this directory is not an endorsement.